DDIT3 and neoplasm: Carfilzomib, targeting K-RAS(+) and cetuximab-resistant colorectal cancer, operates by upregulating UPR downstream CHOP and ATF6 expression, and enhancing apoptotic pathways through caspase-3/7 for anti-tumor activity [99].